Trial Search Results

Study Evaluating Intravitreal hI-con1™ in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

The purpose of this study is to evaluate the safety, biological activity and pharmacodynamic effect of repeated intravitreal doses of hI-con1 0.3 mg administered as monotherapy and in combination with ranibizumab 0.5 mg compared to ranibizumab 0.5 mg monotherapy in treating patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Iconic Therapeutics, Inc.

Stanford Investigator(s):


  • Biological: hI-con1
  • Biological: ranibizumab
  • Other: Sham injection


Phase 2


Inclusion Criteria:

   - Males or females of any race at least 50 years of age

   - Active primary Choroidal Neovascularization (CNV) secondary to Age-Related Macular
   Degeneration (AMD) in the study eye

   - Best Corrected Visual Acuity (BCVA) of 70 to 24 letters (worse than 20/40 up to
   20/320) in the study eye

Exclusion Criteria:

   - Monocular patient or patient with a BCVA of 35 or fewer letters (20/200 or worse) in
   the better seeing eye

   - Any prior treatment of CNV or advanced AMD in the study eye, except for dietary
   supplements or vitamins

   - Any intraocular or ocular surface surgery (including cataract surgery and laser
   procedures) in the study eye within 3 months

   - Vitrectomy in the study eye

   - Hereditary or chronic hemorrhagic or coagulopathy conditions (i.e., hemophilia)

Ages Eligible for Study

50 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting